Vyripharm Enterprises Inc and ABB, Inc. are collaborating.  In the design and development of automation and robotics to enhance the testing laboratory platform for public health and public safety

Vyripharm Enterprises Inc and ABB, Inc. are collaborating. In the design and development of automation and robotics to enhance the testing laboratory platform for public health and public safety

Houston – (work wire) – Vyripharm Enterprises Inc. (VEI), a Texas biopharmaceutical/biotech company headquartered at Texas Medical Center (TMC) in Houston, and ABB Robotics, a global technology leader headquartered in Zurich, Switzerland, have signed an agreement toward the development of an automated laboratory testing platform.

The platform will allow quality control of raw materials for new pharmaceutical compounds using a unique and comprehensive platform developed to allow the approval of tested samples according to established standards. This fully automated automated platform will be the first of its kind and will support data capture for use in research and development efforts within industry and health organizations.

“We are very pleased to work with Vyripharm to develop process quality and automation,” said Dr. Jose Colados, direct director of ABB Life Sciences and Healthcare Robotic Solutions. “ABB’s automated solutions will enhance process productivity and sample traceability which, when combined with the Vyripharm process and software, will improve productivity and improve processes, leading to a significant advance in the future of patient care.”

Under the terms of the partnership, VEI will provide identification of the process, intellectual property (IP), equipment, software and associated funds. ABB will provide the latest automation and robotics software to demonstrate the operational functionality of the integrative platforms. Two pilot sites, located in Texas and Colorado, are currently under construction and expected to be operational in 2023, with other sites planned across the United States and internationally.

“The rapid growth of the biopharmaceutical supply chain has led to the need for standardized testing to ensure that the methods and devices used in the testing process produce equivalent results across various laboratories,” said John W. Shadle, RPh, Managing Director, QA/QC of VEI. “VEI has developed a process and protocol To achieve this goal. We look forward to working with ABB to realize this concept, and make it available for use throughout the United States and the world.”

In 2019, ABB opened the world’s first dedicated research facility for life sciences and healthcare (ABB Life Sciences and Healthcare Solutions), at the Institute of Innovation at Texas Medical Center (TMC). ABB Life Sciences and Healthcare Solutions hopes to advance the life sciences and healthcare industries, including the production of pharmaceutical and medical devices and laboratory automation. ABB Robotics collaborates with the medical community to co-develop innovative automation technologies that help hospitals and laboratories improve productivity and improve operations. A collaborative effort between ABB and VEI is turning this concept into reality in the biopharmaceutical industry, promoting healthcare and public safety. Implementation of this process will support improvements in quality, capacity and cost of operations within the industry.

“With the upcoming new legislation submitted to Congress for review, it is critical that a robust regulatory framework for testing, tracing, tracing, certification, and verification of all new pharmaceutical products in the United States is established in order to protect US citizens and provide standardization across the board,” said Dr. Elias Jackson, Vice President. First for Government and Science for Veriparm Enterprises: American Industrial Supply Chain Points for New Pharmaceuticals.” ABB Life Sciences and Healthcare Solutions is the leader in integrating automation across the life sciences supply chain. We are excited to partner with ABB in this effort.”

About Vyripharm Enterprises Inc.

Vyripharm is a biopharmaceutical/biotech innovator in personalized medicine with a focus on integrating conventional and alternative medicine. Our goal is to ensure the security of agricultural medicines through our commitment to public health and safety. Vyripharm Enterprises, Inc. Foundation patents in safety certification and regulation of agropharmaceutical products in the United States and 40 other countries around the world. The current diagnostic and therapeutic areas of Vyripharm are infectious diseases, neurological disorders, and cancer.

About ABB:

ABB is a leading global technology company that is energizing the transformation of society and industry for a more productive and sustainable future. By connecting software to its portfolio of electricity, robotics, automation and motion, ABB is pushing the boundaries of technology to push performance to new levels. With a history of excellence spanning more than 130 years, the success of ABB is driven by nearly 105,000 talented employees in more than 100 countries.

#Vyripharm #Enterprises #ABB #collaborating #design #development #automation #robotics #enhance #testing #laboratory #platform #public #health #public #safety

Leave a Comment

Your email address will not be published. Required fields are marked *